LOW-GRADE SEROUS OVARIAN CANCER
Clinical trials for LOW-GRADE SEROUS OVARIAN CANCER explained in plain language.
Never miss a new study
Get alerted when new LOW-GRADE SEROUS OVARIAN CANCER trials appear
Sign up with your email to follow new studies for LOW-GRADE SEROUS OVARIAN CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Triple-Drug attack on rare ovarian cancer
Disease control Recruiting nowThis study is testing whether a combination of three medications—avutometinib, defactinib, and letrozole—can effectively treat low-grade serous ovarian cancer. It is for patients who are not candidates for complete initial surgery or who still have measurable disease after surger…
Matched conditions: LOW-GRADE SEROUS OVARIAN CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New Two-Drug combo trial offers hope for women with recurrent ovarian cancer
Disease control Recruiting nowThis study is testing whether a new combination of two oral drugs (avutometinib and defactinib) works better than current standard treatments for women whose low-grade serous ovarian cancer has returned after prior therapy. The trial will involve about 270 participants worldwide …
Matched conditions: LOW-GRADE SEROUS OVARIAN CANCER
Phase: PHASE3 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC
-
New hope for Tough-to-Treat gynecologic cancers
Disease control Recruiting nowThis study is testing a new drug called ubamatamab, given alone or with another drug (cemiplimab), for people with recurrent ovarian, fallopian tube, peritoneal, or endometrial cancers. The main goals are to find a safe and effective dose and to see if the treatment can shrink tu…
Matched conditions: LOW-GRADE SEROUS OVARIAN CANCER
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Mar 06, 2026 15:37 UTC